New York Assembly Bill A05412

New York 2025-2026 Regular Session

• Introduced: 2/13/25
• Refer: 2/13/25
• Refer: 1/7/26
• Report Pass: 3/17/26
• Refer: 3/17/26
• Report Pass: 5/5/26
• Engrossed: 5/11/26
• Refer: 5/11/26

Caption

Establishes the statewide fibroid study program to study fibroids, the treatment of fibroids, potential barriers to the access of treatment for fibroids, and differences in symptoms and access to treatment for women of color.

Impact

If enacted, A05412 would mandate the Department of Health to conduct extensive evaluations regarding the existing research and treatment methodologies related to fibroids. One of the critical components of the bill is to identify barriers that prevent women, particularly women of color, from receiving adequate treatment. This provision highlights the Legislature's commitment to understanding and addressing systemic inequities in health care access and outcomes.

Summary

Bill A05412, also known as the Statewide Fibroid Study Program Act, aims to establish a comprehensive study program under the New York State Department of Health to investigate the occurrence and treatment of fibroids, a significant health issue affecting many women. The bill emphasizes a targeted approach to addressing health disparities by specifically evaluating the impact of fibroids on women of color, recognizing that these groups may face different barriers in accessing treatment and may experience different symptoms.

Contention

While the bill has garnered support for its focus on women’s health and the specific challenges faced by underserved communities, there are potential concerns regarding funding and implementation. Critics may question how effectively the study will translate into actionable solutions for improving treatment access and outcomes. Additionally, discussions may arise about ensuring that the recommendations produced by this program are prioritized within the broader public health agenda and effectively integrated into existing health policy frameworks.